Targeting core GC groups: feasibility and impact

Wednesday, June 11, 2014: 10:00 AM

Grand Ballroom A/B/C/D1

Michel Alary, MD, PhD, Population Health and Optimal Health Practices Research Unit, CHU-HSS, Québec, QC, Canada

Will screening certain core risk groups have an impact on the emergence and spread of drug resistant GC? If so, how do we implement the programs?

35122 Targeting core GC groups: feasibility and impact